Publications by authors named "Joaquim Figueiredo"

Intrusive luxation is one of the most severe types of dental trauma. The occurrence of pulp necrosis in intruded teeth with open apices is 100%. The risk of development of inflammatory or replacement root resorptions is high.

View Article and Find Full Text PDF

The application of a new and simple method of facial cutaneous detachment using specially designed bifaceted rigid steel wands called Dilson Luz Vascular Dilation Wands is described. These wands considerably reduce the bleeding during face-lift surgery, reducing both postoperative hematomas and the risk of facial nerve injury. This technique involves stretching the blood vessels to the point of rupture by inserting progressively larger wands.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate how rifampin, a CYP3A4 enzyme inducer, affects the pharmacokinetics of the immunosuppressant everolimus in healthy subjects.
  • Results showed that rifampin significantly elevated the urinary excretion of 6beta-hydroxycortisol, indicating strong enzyme induction, which led to a 172% increase in the clearance of everolimus and reduced its maximum concentration by an average of 58%.
  • The findings suggest that when everolimus is prescribed alongside rifampin, healthcare providers should consider using alternative medications with less enzyme induction or adjust the everolimus dosage based on therapeutic monitoring.
View Article and Find Full Text PDF

Study Objective: To quantify the influence of a high-fat meal on the oral bioavailability of the immunosuppressant everolimus in a single-dose study in healthy subjects and to confirm the results in a small food-effect screening assessment in patients with renal transplants who were receiving multiple-dose everolimus.

Design: Randomized, open-label, crossover, single-dose study and confirmatory screening.

Setting: Phase 1 unit for the single-dose study and two German hospitals for the patient screening.

View Article and Find Full Text PDF

Everolimus is an immunosuppressant intended for use with cyclosporine in acute-rejection prophylaxis following organ transplantation. The possibility of a drug interaction of cyclosporine on everolimus was assessed. In this randomized, two-period, crossover study, 24 healthy subjects received a single oral dose of 2 mg everolimus alone and with one of two cyclosporine formulations: either 175 mg Neoral or 300 mg Sandimmune.

View Article and Find Full Text PDF